Trends & Forecasts

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems; we ask experts about the future of advanced medicine.

We dive into the archive of 2022 for insight and inspiration – this time with Kowid Ho

Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Why the ability to design therapeutics based on glycobiology will make a mark on pharma R&D.

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Experts explain why these are two important areas to watch in the near future of pharma R&D.

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report